A composite probiotic composition

Abstract

The application discloses a kind of composite probiotic compositions.The provided composite probiotic compositions include: composite probiotic, prebiotics, hanfang components and dispensing agent;The composite probiotic includes a plurality of core bacteria and a plurality of compatible bacteria, and the compatible bacteria include lactobacillus rhamnosus HN001 and bifidobacterium lactis HN019;The hanfang component includes poria cocos and coix seed;The dispensing agent includes lactitol.The probiotic composition provided by the application improves the affinity and proliferation rate of the composite probiotic and the intestinal tract by compounding the core bacteria with a plurality of compatible bacteria and setting specific two bacilli in the compatible bacteria, in combination with the synergistic effect of unique hanfang components and lactitol, thereby achieving remarkable efficacy in improving constipation.

Description

TECHNICAL FIELD

[0001] The present application relates to a composite probiotic composition, belonging to the technical field of biological agents. BACKGROUND

[0002] The description in this section is provided only for convenience for the understanding of the present disclosure, and does not constitute the prior art.

[0003] A variety of intestinal problems are related to intestinal flora imbalance, such as inflammatory bowel disease (IBD): it has been fully proven that the diversity and richness of intestinal microorganisms of IBD patients are significantly reduced, which is called dysbiosis, and the excessive or unbalanced immune response of the intestinal symbiotic microorganisms produces mucosal damage. Colorectal cancer (CRC) research observations found that a large amount of alcohol and low fiber and high fat diet are significantly associated with changes in the structure, distribution and metabolism of the colon microbiota, which may increase the incidence of colorectal cancer. Irritable bowel syndrome (IBS) is a functional bowel disease that often causes abdominal pain, diarrhea, cramping, diarrhea and constipation, and studies have found that IBS patients have a higher number of Streptococcus and Clostridium in the intestine, and fewer Bacteroides, and there is an intestinal flora imbalance.

[0004] Studies have shown that increasing the richness of intestinal flora by ingesting probiotics can improve intestinal diseases, and fecal microbiota transplantation (FMT) can reconstruct the intestinal flora of healthy bacteria to improve intestinal inflammation. Studies have shown that by screening the feces of healthy intestinal bacteria and providing them to the diseased gastrointestinal tract, the intestinal flora can be reconstructed to inhibit pathogenic bacteria, which can be used as a treatment method for patients with difficult infections that are ineffective for repeated or conventional treatment.

[0005] And how to play the combined effect of multiple probiotics becomes the key to achieving good results in this field.

[0006] It should be noted that the above introduction to the technical background is only to facilitate a clear and complete description of the technical solutions of the present application, and to facilitate the understanding of those skilled in the art. The above technical solutions cannot be considered as known to those skilled in the art merely because they are described in the background section of the present application. SUMMARY

[0007] The technical problem to be solved by the present application is to provide a composite probiotic composition. The purpose is to fully exert the anti-constipation effect of the probiotic composition by compounding multiple probiotics and other components.

[0008] In order to solve the above technical problem, the present application provides a composite probiotic composition, which comprises: composite probiotics, prebiotics, Hanfang components and a blending agent.

[0009] The complex probiotic bacteria comprise a plurality of core bacteria and a plurality of compatible bacteria, the compatible bacteria comprising lactobacillus rhamnosus HN001 and bifidobacterium lactis HN019; the Han recipe component comprises poria cocos and coix seed; and the formulation agent comprises lactitol.

[0010] In a second aspect, the application further provides a use of the complex probiotic bacteria composition in the preparation of an anti-constipation food or drug.

[0011] By means of the above technical solutions, the application has the following beneficial effects:

[0012] The probiotic bacteria composition provided by the application improves the affinity and proliferation rate of the complex probiotic bacteria to the intestinal tract by compounding the core bacteria with a plurality of compatible bacteria and arranging two specific bacteria in the compatible bacteria, and improves the effect of improving constipation by means of the synergistic effect of the unique Han recipe component and lactitol. DETAILED DESCRIPTION

[0013] The technical solutions in the embodiments of the application will be described clearly and completely below. Obviously, the described embodiments are only a part of the embodiments of the application, rather than all the embodiments of the application. Based on the embodiments in the application, all other embodiments obtained by a person of ordinary skill in the art without creative work fall within the protection scope of the application.

[0014] It should be noted that, in the description of the application, the terms "first", "second", and the like are only used for description purposes and to distinguish similar objects, and there is no prior or posterior order between them, nor can they be understood as indicating or implying relative importance. In addition, in the description of the application, unless otherwise specified, the meaning of "a plurality of" is two or more.

[0015] The embodiments of the application first provide a complex probiotic bacteria composition, which comprises: complex probiotic bacteria, prebiotics, a Han recipe component, and a formulation agent. The complex probiotic bacteria comprise a plurality of core bacteria and a plurality of compatible bacteria, the compatible bacteria comprising lactobacillus rhamnosus HN001 and bifidobacterium lactis HN019; the Han recipe component comprises poria cocos and coix seed; and the formulation agent comprises lactitol.

[0016] There are a lot of related researches and literatures on lactobacillus rhamnosus HN001 and bifidobacterium lactis HN019, but generally, the researches are on the independent effects of the two, for example, lactobacillus rhamnosus HN001 can reduce the incidence of gestational diabetes and reduce staphylococcus aureus infection, and bifidobacterium lactis HN019 can alleviate the symptoms of metabolic syndrome and chronic periodontitis, but there is generally a lack of research on the complex synergistic effect of the two.

[0017] The application finds that the addition of Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 as compatible bacteria in a composite system of multiple probiotics can significantly improve the anti-constipation effect of probiotics; in addition, some Han formula components and dispensing agents also need to be combined to play the above-mentioned role; in particular, lactitol, which is a disaccharide alcohol derived from lactose, is prepared by hydrogenating and reducing the glucose group in lactose. Lactitol has good thermal stability and acid-base stability: lactitol is not easy to decompose, does not easily discolor, and is resistant to acid and alkali, which is not possessed by oligosaccharide prebiotics. Lactitol, as a sweet sugar alcohol, also serves as an effective proliferation factor for probiotics, which can promote the rapid proliferation of probiotics in the application and combine with the intestinal epithelium, shorten the onset time and enhance the biological efficacy.

[0018] In addition, among the added Han formula components in the application, Poria cocos is a good traditional Chinese medicine with a particularly wide range of applications. Poria cocos is mainly a spleen and stomach medicine, and its main function is to tonify the spleen and stomach. Patients with spleen and stomach weakness, indigestion, fatigue, weakness, fatigue, abdominal distension, loss of appetite, loose stools, and diarrhea often use Poria cocos. In addition, Poria cocos can also drain water and remove dampness, and can be used for edema caused by various water retention. That is, various edema, such as difficulty urinating and abdominal distension. Poria cocos can calm the heart and mind, and can treat insomnia, i.e., difficulty falling asleep and easy waking.

[0019] Yiren has the following effects: first, Yiren has the effect of draining water and reducing swelling, which can remove excess water in the body and remove dampness in the body, and can be used for symptoms such as difficulty urinating. Second, Yiren has the effect of invigorating the spleen and can be used for spleen deficiency. Third, for women, Yiren has the effect of whitening. Fourth, Yiren has the effect of benefiting the lungs and can drink more Yiren water when coughing. Fifth, the nutrients contained in Yiren have the effect of resisting cancer.

[0020] In the application, the main function of the two Han formula components Poria cocos and Yiren is still to promote the affinity of probiotics with the intestinal tract and improve the effect.

[0021] In some embodiments, the core bacteria can include Lactobacillus fermentum CCTCC M 2013511, Lactobacillus plantarum YS4, Lactobacillus rhamnosus LRYZU021, and Lactobacillus plantarum KLDS1001. The selection of the core bacteria used in the preferred embodiments of the application is as shown above, but it does not mean that the embodiments of the application are limited to this. Certain changes can be made to the above-mentioned core bacteria, such as addition, subtraction or replacement, which can also have equivalent effects. Generally speaking, the ratio relationship between different probiotics of the core bacteria can not be specifically limited, for example, the number of each strain is in equal proportion (1:1:1:1), or any one of them can be up and down by 50%.

[0022] In some embodiments, the compatible bacteria further include Lactobacillus helveticus LZ-R-5, Lactobacillus plantarum LP3A. As mentioned above, the main effective components of the compatible bacteria are Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019, and the added auxiliary compatible bacteria, such as the above-mentioned Lactobacillus helveticus LZ-R-5 and Lactobacillus plantarum LP3A, are usually added in equal proportions, (1:1), which can be floated up and down by 50%.

[0023] In some embodiments, the preparation agent further includes resistant dextrin. Resistant dextrin belongs to low molecular water-soluble dietary fiber. As a low-calorie soluble food raw material, resistant dextrin has the effect of regulating the body, can play the value of dietary fiber, can help reduce blood sugar, especially for patients with high blood sugar or hyperglycemia, can reduce the body's demand for insulin, and can inhibit the body's absorption of external sugar, so the effect on reducing blood sugar is very outstanding.

[0024] In some embodiments, the prebiotic includes fructooligosaccharides and stachyose.

[0025] Fructooligosaccharides are not hydrolyzed by human digestive enzymes, have non-digestive and insulin-independent properties, and can effectively reduce fasting blood sugar levels when consumed. Fructooligosaccharides promote the colonization of beneficial bacteria such as Lactobacillus, Bifidobacterium, and Streptococcus in the digestive tract, inhibit the growth of harmful bacteria, improve the intestinal flora, and indirectly achieve the nutritional and growth-promoting effects on the human body. It promotes the formation of B vitamins and folic acid, maintains the normal function of the nervous system, promotes digestion and metabolism, cleanses the intestines, lubricates the intestines, relieves constipation and hemorrhoids, prevents rectal and colon cancer, reduces liver toxins, and enhances human immunity.

[0026] Stachyose enters the human body and is not digested by human digestive enzymes, but enters the colon completely. Stachyose is hydrolyzed into acetic acid and lactic acid, which reduces the pH of the intestinal wall and inhibits the growth of harmful bacteria in the intestine, thereby playing a role in regulating the intestinal microecological balance. Stachyose is rich in active factors and can directly adsorb toxic substances and pathogenic bacteria in the gastrointestinal tract, thereby enhancing human immunity and having the effect of removing lead and cleansing the intestines. It helps absorption: stachyose can help weak women or the elderly effectively absorb nutrients such as calcium, magnesium, and phosphorus, thereby improving physical fitness.

[0027] However, it should be noted that the prebiotic components used in the present application are not limited to the combination of fructooligosaccharides and stachyose, and usually two or more prebiotic components are set in equal weight parts, which can also be appropriately floated (for example, ± 50%).

[0028] As for the specific ratio, in some embodiments, the number ratio of the core bacteria to the compatible bacteria is 1:(0.5-1.5).

[0029] In some embodiments, the ratio of the number of Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 in the compatible bacteria is 1:(0.5-1.5).

[0030] In some embodiments, the mass ratio of the complex probiotic, prebiotic, Han recipe component, and formulation is (1-1.5):(0.5-1):(3-5):(5-10).

[0031] In some embodiments, the form of the complex probiotic composition is a solid powder or a liquid biological preparation.

[0032] The second aspect of the embodiments of the present application also provides the use of the complex probiotic composition provided by any of the above embodiments in the preparation of an anti-constipation food or drug.

[0033] The technical solutions of the present application are further illustrated by several embodiments as follows, but it should be pointed out that the following embodiments are only part of the representative cases in the feasible implementation modes of the present application, and not all the embodiments. The following embodiments are only used for illustrative description of the present application, and do not limit the protection scope of the present application.

[0034] Example 1

[0035] The present embodiment provides a probiotic composition containing the following components (weight parts in parentheses):

[0036] Formulation: lactitol, resistant dextrin; prebiotic: fructooligosaccharide, stachyose; Han recipe component: poria cocos, coix; core bacteria: Lactobacillus fermentum CCTCC M 2013511, Lactobacillus plantarum YS4, Lactobacillus rhamnosus LRYZU021, Lactobacillus plantarum KLDS1001; compatible bacteria: Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, Lactobacillus plantarum Lp3a, Lactobacillus helveticus LZ-R-5.

[0037] Among them, the mass ratio of core bacteria, compatible bacteria, prebiotic, Han recipe component and formulation is 0.5:0.5:1:4:8. The number ratio of each strain is about equal proportion.

[0038] The product is a bar-shaped packaged powder, with a bacterial number of 50 billion per bar and a weight of 2 grams per bar.

[0039] Comparative Example 1

[0040] This comparative example is basically the same as Example 1, the main difference is:

[0041] Remove Lactobacillus rhamnosus HN001 and replace it with an equal amount of Bifidobacterium lactis HN019.

[0042] Comparative Example 2

[0043] This comparative example is generally the same as Example 1, the main difference being that:

[0044] Lactobacillus rhamnosus HN019 is removed and replaced with an equal amount of Lactobacillus rhamnosus HN001.

[0045] Comparative Example 3

[0046] This comparative example is generally the same as Example 1, the main difference being that:

[0047] Lactitol is removed and replaced with an equal amount of resistant dextrin.

[0048] Test Example 1

[0049] This test example is a control test of the probiotic composition provided in Example 1 and Comparative Examples 1-3 under the factor of constipation, as shown below:

[0050] Construction of a constipation mouse model: The modeling drug is compound diphenoxylate.

[0051] Modeling: After one week of adaptive feeding of the test mice, 3.5% compound diphenoxylate was dissolved in sterilized drinking water to replace the normal drinking water of the mice, and the mice were allowed to freely obtain it for 7 consecutive days.

[0052] Test grouping design:

[0053] Control group: 10, normal healthy mice, drinking normal sterilized water, and the gavage medium is PBS.

[0054] Model group: 10, 3.5% compound diphenoxylate dissolved in sterilized water to replace the normal drinking water for disease modeling, for 7 consecutive days. After the modeling started, the body weight, diarrhea, and bloody stool of the mice were monitored every day to evaluate whether the model was successfully established, and the gavage medium was PBS.

[0055] Probiotic treatment group: a total of 4 groups, 10 mice in each group. The mice freely drank 3.5% compound diphenoxylate-containing drinking water every day, and were treated with the probiotic composition provided in Example 1, Comparative Examples 1-3, respectively. Once a day, 200 μL (containing 1 x 109 cfu / mL of live bacteria) per mouse, for 7 consecutive days.

[0056] Symptomatology observation: The activity state, daily stool number, and degree of stool dryness of the mice were observed every day after the start of the test, and the evaluation was made according to the severity.

[0057] The evaluation results are shown in the table below, where the numerical value represents the number of abnormalities.

[0058]

[0059] Example 2

[0060] The present embodiment provides a probiotic composition containing the following components (the weight parts are in the brackets):

[0061] Formulation agent: lactitol, resistant dextrin; prebiotic: fructooligosaccharide, stachyose; Han recipe component: poria cocos, coix; core bacteria: Lactobacillus fermentum CCTCC M 2013511, Lactobacillus plantarum YS4, Lactobacillus rhamnosus LRYZU021, Lactobacillus plantarum KLDS1001; compatible bacteria: Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, Lactobacillus plantarum Lp3a, Lactobacillus helveticus LZ-R-5.

[0062] The mass ratio of the core bacteria, the compatible bacteria, the prebiotic, the Han recipe component, and the formulation agent is 1:0.5:0.5:3:5. The quantity ratio of each bacterial species is approximately equal.

[0063] The product is a powder packed in strips, with a bacterial number of 70 billion per strip and a weight of 2 grams per strip.

[0064] Embodiment 3

[0065] The present embodiment provides a probiotic composition containing the following components (the weight parts are in the brackets):

[0066] Formulation agent: lactitol, resistant dextrin; prebiotic: fructooligosaccharide, stachyose; Han recipe component: poria cocos, coix; core bacteria: Lactobacillus fermentum CCTCC M 2013511, Lactobacillus plantarum YS4, Lactobacillus rhamnosus LRYZU021, Lactobacillus plantarum KLDS1001; compatible bacteria: Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, Lactobacillus plantarum Lp3a, Lactobacillus helveticus LZ-R-5.

[0067] The mass ratio of the core bacteria, the compatible bacteria, the prebiotic, the Han recipe component, and the formulation agent is 0.5:1:1:5:10. The quantity ratio of each bacterial species is approximately equal.

[0068] The product is a powder packed in strips, with a bacterial number of 30 billion per strip and a weight of 2 grams per strip.

[0069] Embodiment 4

[0070] The present embodiment is generally the same as Embodiment 3, with the main difference being:

[0071] The product is prepared as a liquid biological preparation.

[0072] The same strong effect of preventing constipation as in Embodiment 1 is observed in the above embodiments 1-4, and will not be repeated here.

[0073] Based on the above examples and comparative examples, it can be clear that the probiotic composition provided by the present application improves the affinity and proliferation rate of the compound probiotic bacteria to the intestinal tract by compounding the core bacteria with a plurality of compatible bacteria, and setting specific two bacilli in the compatible bacteria, in combination with the synergistic effect of the unique Han recipe components and lactitol, thereby achieving remarkable effects in improving constipation.

[0074] The above examples are only preferred examples for fully illustrating the present application, and the protection scope of the present application is not limited thereto. Any equivalent replacement or transformation made by the skilled in the art on the basis of the present application is within the protection scope of the present application. The protection scope of the present application is subject to the claims.

Claims

1. A composite probiotic composition, characterized in that, The application relates to a composite probiotic, prebiotic, traditional Chinese medicine component and a preparation agent. The composite probiotic comprises a plurality of core bacteria and a plurality of compatible bacteria, the compatible bacteria comprise lactobacillus rhamnosus HN001 and bifidobacterium lactis HN019, the traditional Chinese medicine component is selected from poria cocos and coix seed, and the preparation agent comprises lactitol, the core bacteria comprise lactobacillus fermentum CCTCC M 2013511, lactobacillus plantarum YS4, lactobacillus rhamnosus LRYZU021 and lactobacillus plantarum KLDS1001. The quantity ratio of the core bacteria to the compatible bacteria is 1: (0.5-1.5), the quantity ratio of lactobacillus rhamnosus HN001 to bifidobacterium lactis HN019 in the compatible bacteria is 1: (0.5-1.5), and the mass ratio of the composite probiotic, the prebiotic, the traditional Chinese medicine component and the preparation agent is (1-1.5):(0.5-1):(3-5):(5-10). The compatible bacteria further comprise lactobacillus helveticus LZ-R-5 and lactobacillus plantarum LP3A.

2. The complex probiotic composition according to claim 1, characterized in that, The preparation agent further comprises resistant dextrin.

3. The complex probiotic composition according to claim 1, characterized in that, The prebiotic comprises fructooligosaccharide and stachyose.

4. The complex probiotic composition according to claim 1, characterized in that, The composite probiotic composition is in the form of solid powder or liquid biological preparation.

5. The combination probiotic composition according to claim 1, wherein, ​

Images